hyperlipidemia

During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.

In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including: 

• A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid 
• Lessons learned from a long-term outcomes study of people with PBC
• Results from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid

Presenter:

Kris V. Kowdley MD, FAASLD, FACP, FACG
Professor, Elson S. Floyd College of Medicine
Washington State University
Director, Liver Institute Northwest
Seattle, Washington      

Link to reviews of other PBC studies from AASLD 2023: 
https://bit.ly/3RvXXEI

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.

In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including: 

• A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acid
• A study that explored racial differences as they relate to the presentation and diagnosis of PBC

Presenter: 
Stuart C. Gordon, MD, FAASLD
Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan

Link to commentary:
https://bit.ly/3GzRMt2

Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.

In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: 

• A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)
• A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCA
• A retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBC

Presenter: 

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Link to commentary:
https://bit.ly/47PmGdc

Link to reviews of other PBC studies from AASLD 2023: 
https://bit.ly/3RvXXEI

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:

• Hyperlipidemia and cardiovascular disease risk among people living with HIV
• Recommendations for lipid screening for people living with HIV
• Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
• How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
  • Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
  • Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
• How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
• How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database

Maunank Shah, MD, PhD 
Associate Professor 
Infectious Diseases 
Johns Hopkins University 
Baltimore, Maryland 

Link to full program: bit.ly/3pwaH2Y

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.

Topics discussed include:

• Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginase
• Indirect methods for measuring asparaginase activity
• Strategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosis
• Considerations for use of asparaginase in special populations (eg, high BMI, older age)

Presenters:

Program Director
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts

Emily Curran, MD
Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Kjeld Schmiegelow, MD, DMSci
Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Content based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.

Link to full program:
http://bit.ly/3YXkLyj

In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes:

• DHHS Treatment Guideline recommendations
• Choosing among first-line recommended integrase inhibitors
• Recommended regimens for rapid ART start
• Select key studies in treatment-naïve adults:
  • AMBER study of virologic response with DRV/COBI/FTC/TAF vs DRV/COBI + TFC/TDF
  • DRIVE-AHEAD and DRIVE-FORWARD efficacy study results, including resistance analyses of DOR + 2 NRTIs vs EFV or (DRV + RTV) + 2 NRTIs
  • Safety and efficacy results from GEMINI-1 and GEMINI comparing DTG + 3TC vs DTG + FTC/TDF
• The current/possible role of boosted PIs and NNRTIs
• Selection considerations between TDF and TAF

Presenter:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides:
https://bit.ly/3PYy1zn

Learn about the important Hyperlipidemia concepts to know including: Differential Dx, Dx Test, Primary Prevention Measures and More!